Immunotherapy in Acute Myeloid Leukemia: Where We Stand
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | G. Martinelli | T. Kadia | F. Ravandi | E. Jabbour | N. Daver | C. Dinardo | A. Romano | G. Visani | A. Curti | C. Cerchione | A. Isidori | F. Loscocco | A. Burguera
[1] M. Konopleva,et al. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study , 2021, Blood Cancer Journal.
[2] J. Esteve,et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study , 2020 .
[3] A. Harrington,et al. A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML , 2020 .
[4] M. Konopleva,et al. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2020 .
[5] M. Berger,et al. Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study , 2020 .
[6] F. Ravandi,et al. Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study , 2020, Blood.
[7] D. Neuberg,et al. Safety and Efficacy of Decitabine Plus Ipilimumab in Relapsed or Refractory MDS/AML in the Post-BMT or Transplant Naïve Settings , 2020 .
[8] S. Rutella,et al. Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia , 2020 .
[9] J. Khoury,et al. CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies , 2020, Cancers.
[10] T. Yau,et al. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. , 2020, Blood advances.
[11] P. Vyas,et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter , 2020, Blood Cancer Journal.
[12] D. Tribble,et al. A first in human clinical trial assessing the safety and immunogenicity of transcutaneously delivered enterotoxigenic Escherichia coli fimbrial tip adhesin with heat-labile enterotoxin with mutation R192G. , 2020, Vaccine.
[13] Jeffrey S. Miller,et al. Exploring the NK cell platform for cancer immunotherapy , 2020, Nature Reviews Clinical Oncology.
[14] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[15] N. Giuliani,et al. Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma , 2020, Journal of clinical medicine.
[16] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[17] B. Ryu,et al. The Art and Science of Selecting a CD123-Specific Chimeric Antigen Receptor for Clinical Testing , 2020, Molecular therapy. Methods & clinical development.
[18] Danielle E. Dettling,et al. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[19] A. Anderson,et al. Tim-3 finds its place in the cancer immunotherapy landscape , 2020, Journal for immunotherapy of cancer.
[20] Z. Izsvák,et al. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] P. Paschka,et al. Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). , 2020 .
[22] M. Konopleva,et al. A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies. , 2020 .
[23] P. Vyas,et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. , 2020 .
[24] H. Einsele,et al. The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types , 2020, Cancer.
[25] Catherine J. Wu,et al. A multicenter, phase I study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. , 2020, Blood.
[26] D. Phillips,et al. Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions , 2020, Frontiers in Immunology.
[27] Shaohua Chen,et al. Expression patterns of immune checkpoints in acute myeloid leukemia , 2020, Journal of Hematology & Oncology.
[28] I. Gojo,et al. Immune escape and immunotherapy of acute myeloid leukemia. , 2020, The Journal of clinical investigation.
[29] P. Sharma,et al. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors , 2020, Cancer.
[30] A. Chari,et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches , 2020, Leukemia.
[31] T. Chevassut,et al. Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia , 2020, Current Oncology Reports.
[32] M. Konopleva,et al. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. , 2020, Cancer discovery.
[33] I. Weissman,et al. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies , 2020, Frontiers in Oncology.
[34] M. Konopleva,et al. Venetoclax for AML: changing the treatment paradigm. , 2019, Blood advances.
[35] R. Schlenk,et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents , 2019, Leukemia.
[36] M. Konopleva,et al. Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) , 2019, Blood.
[37] R. Varadhan,et al. Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients , 2019, Blood.
[38] J. Esteve,et al. Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) , 2019, Blood.
[39] F. Ravandi,et al. Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) , 2019, Blood.
[40] J. Serody,et al. Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML , 2019, Blood.
[41] A. Harrington,et al. Lintuzumab Ac-225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML: Interim Results of a Phase I Study , 2019, Blood.
[42] Kristen L. Jones,et al. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. , 2019, The Journal of clinical investigation.
[43] P. Sharma,et al. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study. , 2019, The Lancet. Haematology.
[44] Kongming Wu,et al. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity , 2019, Molecular Cancer.
[45] T. Waldmann,et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. , 2019, Blood advances.
[46] B. Brodská,et al. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations , 2019, International journal of molecular sciences.
[47] Hui Wang,et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies , 2019, Proceedings of the National Academy of Sciences.
[48] S. Amadori,et al. Genomic profiling and predicting treatment response in acute myeloid leukemia. , 2019, Pharmacogenomics.
[49] Thomas M. Schmitt,et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant , 2019, Nature Medicine.
[50] A. Goldberg,et al. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets , 2019, Current Oncology Reports.
[51] T. Nakamaki,et al. Impact of CD123 expression, analyzed by immunohistochemistry, on clinical outcomes in patients with acute myeloid leukemia , 2019, International Journal of Hematology.
[52] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[53] P. Sharma,et al. The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia , 2018, Cancer.
[54] P. Sharma,et al. Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. , 2018, Cancer discovery.
[55] K. Metzeler,et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. , 2018, Blood.
[56] P. Moore,et al. A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules , 2018, Blood.
[57] P. Paschka,et al. A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) , 2018, Blood.
[58] D. Saul,et al. CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells , 2018, Journal of Immunotherapy for Cancer.
[59] G. Uy,et al. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia , 2018, Current Hematologic Malignancy Reports.
[60] P. Westervelt,et al. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[61] K. Spiekermann,et al. Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells , 2018, Oncoimmunology.
[62] N. Hosen,et al. Wilms tumour 1 peptide vaccine as a cure‐oriented post‐chemotherapy strategy for patients with acute myeloid leukaemia at high risk of relapse , 2018, British journal of haematology.
[63] W. Hiddemann,et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML , 2018, Leukemia.
[64] S. Amadori,et al. Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach , 2018, Cancers.
[65] M. Konopleva,et al. Nivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients. , 2018 .
[66] J. Byrd,et al. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors , 2018, Haematologica.
[67] P. Sharma,et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes , 2018, Leukemia.
[68] T. Chittenden,et al. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. , 2018, Blood advances.
[69] H. Ljunggren,et al. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML , 2018, Clinical Cancer Research.
[70] David A Scheinberg,et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. , 2018, Blood advances.
[71] H. Einsele,et al. CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib , 2018, Leukemia.
[72] F. Ravandi,et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. , 2018, Blood.
[73] D. Porter,et al. Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells , 2017 .
[74] B. Wood,et al. Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial , 2017 .
[75] K. Rezvani,et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. , 2017, Blood.
[76] H. Goossens,et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. , 2017, Blood.
[77] C. Rooney,et al. Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.
[78] T. Arvedson,et al. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing , 2017, PloS one.
[79] M. Subklewe,et al. Recent developments in immunotherapy of acute myeloid leukemia , 2017, Journal of Hematology & Oncology.
[80] Xingchun Gou,et al. Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy , 2017, Front. Immunol..
[81] Nicole L. Wittwer,et al. High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression. , 2017, Blood advances.
[82] M. Minden,et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission , 2017, Blood Cancer Journal.
[83] P. Sharma,et al. Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML. , 2017 .
[84] Koichi Araki,et al. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent , 2016, Science.
[85] J. Jansen,et al. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients , 2017, Clinical Cancer Research.
[86] A. Bagg,et al. Targeting CLEC12A with Chimeric Antigen Receptor T Cells Can Overcome the Chemotherapy Refractoriness of Leukemia Stem Cells , 2017 .
[87] R. Hills,et al. Expression of CD33 is a predictive factor for effect of Gemtuzumab Ozogamicin at different doses in adult acute myeloid leukemia , 2016, Leukemia.
[88] P. Thall,et al. PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies , 2016, Leukemia.
[89] M. Konopleva,et al. Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD) , 2016 .
[90] A. Hagemeijer,et al. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] A. Rudensky,et al. An essential role for IL-2 receptor in regulatory T cell function , 2016, Nature Immunology.
[92] Catherine J. Wu,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[93] Amy K. Erbe,et al. Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion , 2016, Cancer Immunology, Immunotherapy.
[94] Rebecca Austin,et al. Harnessing the immune system in acute myeloid leukaemia. , 2016, Critical reviews in oncology/hematology.
[95] L. Ruggeri,et al. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients , 2016, Clinical Cancer Research.
[96] F. Gao,et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform. , 2016, Blood.
[97] F. Hodi,et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. , 2016, The New England journal of medicine.
[98] A. Roberts,et al. Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML) , 2015 .
[99] A. Rudensky,et al. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs , 2015, Science.
[100] R. Kischel,et al. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk , 2015, PloS one.
[101] Angel F. Lopez,et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice , 2015, Haematologica.
[102] I. Kerridge,et al. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia , 2015, Leukemia & lymphoma.
[103] C. Sentman,et al. Bispecific T‐cell engagers for cancer immunotherapy , 2015, Immunology and cell biology.
[104] A. Thompson,et al. Early Results of a Phase I/ II Study of Gene Therapy for β-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral βAT87Q -Globin Vector , 2015 .
[105] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[106] James M Wilson,et al. The Next Chapter. , 2015, Human gene therapy.
[107] Quan-shun Wang,et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[108] F. Gao,et al. MYELOID NEOPLASIA Targeting CD 123 in acute myeloid leukemia using a T-cell – directed dual-af fi nity retargeting platform , 2015 .
[109] Michael I. Seider,et al. Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma , 2014 .
[110] A. Roberts,et al. First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse , 2014 .
[111] G. Visani,et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment , 2014, Expert review of hematology.
[112] E. Estey,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. , 2014, The Lancet. Oncology.
[113] W. Leung. Infusions of Allogeneic Natural Killer Cells as Cancer Therapy , 2014, Clinical Cancer Research.
[114] Bin Zhang,et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. , 2014, Blood.
[115] G. Ehninger,et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia , 2014, Blood Cancer Journal.
[116] M. Carroll,et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. , 2014, Blood.
[117] A. Henn,et al. Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.
[118] D. Goldenberg,et al. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy , 2014, mAbs.
[119] R. Kischel,et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.
[120] W. Hiddemann,et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.
[121] U. Testa,et al. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies , 2014, Biomarker Research.
[122] A. Venditti,et al. Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients , 2013, Expert review of hematology.
[123] J. Dipersio,et al. Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®) , 2013 .
[124] L. Naldini,et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. , 2013, Blood.
[125] A. Scott,et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[126] Xiuli Wang,et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. , 2013, Blood.
[127] P. Parren,et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange , 2013, mAbs.
[128] M. Hino,et al. Maintenance of complete remission after allogeneic stem cell transplantation in leukemia patients treated with Wilms tumor 1 peptide vaccine , 2013, Blood Cancer Journal.
[129] R. Larson,et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. , 2013, Blood.
[130] J. Cany,et al. Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice , 2013, PloS one.
[131] A. Rudensky,et al. IL-2–dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells , 2013, The Journal of experimental medicine.
[132] T. D. de Gruijl,et al. Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission , 2013, Oncoimmunology.
[133] G. Ehninger,et al. Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells , 2013, Leukemia.
[134] S. Izumoto. Peptide vaccine. , 2020, Advances in experimental medicine and biology.
[135] C. Craddock,et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] T. Kyo,et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease , 2012, Leukemia.
[137] H. Dombret,et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study , 2012, The Lancet.
[138] N. Hosen,et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission , 2012, Leukemia.
[139] L. Hurton,et al. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells , 2012, PloS one.
[140] A. Vekhoff,et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia , 2012, Investigational New Drugs.
[141] G. Ehninger,et al. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. , 2011, Molecular immunology.
[142] M. Baccarani,et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. , 2011, Blood.
[143] D. Busch,et al. Regulatory T Cells Selectively Control CD8+ T Cell Effector Pool Size via IL-2 Restriction , 2011, The Journal of Immunology.
[144] Harry Dolstra,et al. Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process , 2011, PloS one.
[145] R. Hills,et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] G. Gahrton,et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. , 2010, Cytotherapy.
[147] S. Larson,et al. Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.
[148] Chap T Le,et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. , 2010, Blood.
[149] V. Orian-Rousseau. CD44, a therapeutic target for metastasising tumours. , 2010, European journal of cancer.
[150] C. Pui,et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[151] I. Joosten,et al. High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy , 2010, PloS one.
[152] A. Nesterova,et al. Anti-leukemic activity of Lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia , 2009, mAbs.
[153] T. Gajewski,et al. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.
[154] E. Thiel,et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.
[155] D. Campana,et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.
[156] K. Rezvani,et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.
[157] R. Schlenk,et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. , 2008, Blood.
[158] A. Frankel,et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia , 2008, Leukemia & lymphoma.
[159] R. Hills,et al. Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial. , 2007 .
[160] J. North,et al. Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation1 , 2007, The Journal of Immunology.
[161] M. Martelli,et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. , 2006, Blood.
[162] A. Varki,et al. Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs. , 2006, Experimental hematology.
[163] G. A. Lazar,et al. Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[164] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[165] D. Scheinberg,et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[166] C. Le,et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.
[167] Jonathan A. Cooper,et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. , 2004, Blood.
[168] Lewis L Lanier,et al. NK cell recognition. , 2005, Annual review of immunology.
[169] T. Kyo,et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[170] C. Peschle,et al. Interleukin-3 receptor in acute leukemia , 2004, Leukemia.
[171] L. Allen. Stem cells. , 2003, The New England journal of medicine.
[172] M. Caligiuri,et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. , 2002, Blood.
[173] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.
[174] E. Thiel,et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. , 2002, Blood.
[175] Katia Perruccio,et al. Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants , 2002, Science.
[176] E. Thiel,et al. CD 8 T-cell responses to Wilms tumor gene product WT 1 and proteinase 3 in patients with acute myeloid leukemia , 2002 .
[177] I. Bernstein,et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[178] X. H. Chen,et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[179] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[180] H. Sugiyama,et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product , 2000, Immunogenetics.
[181] J. Radich. Minimal residual disease , 1995, Current opinion in hematology.
[182] T. Akiyama,et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. , 1994, Blood.